ATE326238T1 - Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoff-senfgasen verwendet werden kann - Google Patents

Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoff-senfgasen verwendet werden kann

Info

Publication number
ATE326238T1
ATE326238T1 AT97928507T AT97928507T ATE326238T1 AT E326238 T1 ATE326238 T1 AT E326238T1 AT 97928507 T AT97928507 T AT 97928507T AT 97928507 T AT97928507 T AT 97928507T AT E326238 T1 ATE326238 T1 AT E326238T1
Authority
AT
Austria
Prior art keywords
nitrogen mustard
used together
agent against
myeloma
actives based
Prior art date
Application number
AT97928507T
Other languages
English (en)
Inventor
Akito Chugai Seiyaku Nakamura
Kenichi Chugai Seiyak Akamatsu
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE326238T1 publication Critical patent/ATE326238T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97928507T 1996-06-27 1997-06-27 Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoff-senfgasen verwendet werden kann ATE326238T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16732596 1996-06-27

Publications (1)

Publication Number Publication Date
ATE326238T1 true ATE326238T1 (de) 2006-06-15

Family

ID=15847661

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97928507T ATE326238T1 (de) 1996-06-27 1997-06-27 Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoff-senfgasen verwendet werden kann

Country Status (10)

Country Link
US (3) US6692742B1 (de)
EP (1) EP0923941B1 (de)
JP (1) JP3471195B2 (de)
AT (1) ATE326238T1 (de)
AU (1) AU3276297A (de)
DE (1) DE69735888T2 (de)
DK (1) DK0923941T3 (de)
ES (1) ES2263178T3 (de)
PT (1) PT923941E (de)
WO (1) WO1997049428A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT923941E (pt) * 1996-06-27 2006-09-29 Chugai Pharmaceutical Co Ltd Medicamentos para mieloma a serem utilizados com agentes antitumorais de mostarda nitrogenada
ES2312184T3 (es) 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
AU757873B2 (en) * 1998-09-14 2003-03-06 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP3192528A1 (de) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formularierung anti-il-6r antikörper-enthaltender lösungen die einen zucker als stabilisator beinhalten
EP1523318A4 (de) * 2002-06-24 2007-07-04 Res Dev Foundation Behandlung des humanen multiplen myeloms durch curcumin
ES2626268T3 (es) 2002-09-11 2017-07-24 Chugai Seiyaku Kabushiki Kaisha Método de purificación de proteínas
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
JP2007503475A (ja) 2003-08-26 2007-02-22 リサーチ ディベロップメント ファウンデーション 破骨細胞形成阻害剤およびその使用方法
ES2368741T3 (es) * 2004-02-25 2011-11-21 Dana-Farber Cancer Institute, Inc. Inhibidores del receptor 1 del factor de crecimiento de tipo insulina para inhibir el crecimiento de células tumorales.
WO2005090405A1 (ja) 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha インターロイキン－６受容体に対するヒト型化抗体のサブタイプ
EP2946810A1 (de) * 2005-02-03 2015-11-25 TopoTarget UK Limited Kombinationstherapie mit einem HDAC-Hemmer und Vincristin zur Behandlung von Krebs
US8501818B2 (en) * 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
US20110039943A1 (en) * 2005-03-14 2011-02-17 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
US7872050B2 (en) * 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
BRPI0821417A2 (pt) * 2007-12-26 2015-06-16 Biotest Ag Método para diminuir a adesão de células de estroma a células tumorais que expressam cd138 em células tumorais de um indivíduo em necessidade do mesmo
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
LT2273876T (lt) 2008-03-27 2019-05-27 Helsinn Healthcare Sa Stabilizuotos alkilinimo medžiagų kompozicijos ir jų panaudojimo būdai
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CN104928336B (zh) 2009-10-26 2020-05-08 弗·哈夫曼-拉罗切有限公司 用于生产糖基化免疫球蛋白的方法
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
EP2787007A3 (de) 2010-11-08 2015-03-11 F. Hoffmann-La Roche AG Subkutan verabreichter ANTI-IL-6-Rezeptorantikörper
MX385311B (es) 2011-01-28 2025-03-18 Sanofi Biotechnology Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes.
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
SG11201402887SA (en) 2011-12-08 2014-07-30 Biotest Ag Uses of immunoconjugates targeting cd138
SG10201610869TA (en) 2012-06-26 2017-02-27 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti
EP2983674A4 (de) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutischer nutzen suboptimal verabreichter chemischer verbindungen
BR112015032960B1 (pt) 2013-07-04 2021-01-05 F. Hoffmann-La Roche Ag imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
EP3068803B1 (de) 2013-11-12 2021-01-20 Sanofi Biotechnology Dosierungsschemata zur verwendung von pcsk9 inhibitoren
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
KR20240172758A (ko) 2015-08-18 2024-12-10 리제너론 파아마슈티컬스, 인크. 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
US11484591B2 (en) 2016-02-22 2022-11-01 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
EP3596175A4 (de) 2017-03-17 2021-01-13 The Ohio State Innovation Foundation Nanopartikel zur abgabe von chemopräventiven mitteln
JP7542543B2 (ja) 2019-01-31 2024-08-30 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
CN114651010A (zh) 2019-04-24 2022-06-21 赛诺菲生物技术公司 类风湿性关节炎的诊断和治疗方法
KR20230061198A (ko) 2019-06-04 2023-05-08 사노피 바이오테크놀로지 류마티스성 관절염을 갖는 대상체에서 통증을 치료하기 위한 조성물 및 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
ATE144713T1 (de) * 1989-07-20 1996-11-15 Tadamitsu Kishimoto Antikörper gegen menschlichen interleukin-6- rezeptor
ES2134212T3 (es) * 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
US5882941A (en) * 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
PT923941E (pt) * 1996-06-27 2006-09-29 Chugai Pharmaceutical Co Ltd Medicamentos para mieloma a serem utilizados com agentes antitumorais de mostarda nitrogenada
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer

Also Published As

Publication number Publication date
ES2263178T3 (es) 2006-12-01
DK0923941T3 (da) 2006-09-18
AU3276297A (en) 1998-01-14
EP0923941B1 (de) 2006-05-17
JP3471195B2 (ja) 2003-11-25
PT923941E (pt) 2006-09-29
WO1997049428A1 (en) 1997-12-31
DE69735888D1 (de) 2006-06-22
DE69735888T2 (de) 2006-11-02
EP0923941A4 (de) 2001-12-05
US20040247621A1 (en) 2004-12-09
US6692742B1 (en) 2004-02-17
EP0923941A2 (de) 1999-06-23
US7771723B2 (en) 2010-08-10
US7566453B2 (en) 2009-07-28
JPH1087510A (ja) 1998-04-07
US20020131967A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
DE69735888D1 (de) Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoff-senfgasen verwendet werden kann
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
FI956019L (fi) Eristettyjä peptidejä, jotka muodostavat komplekseja MHC-molekyyli HLA-C-klooni-10:n kanssa, ja niiden käyttö
DK0711140T3 (da) Antimykotisk opløsning til negle
BR9804500B1 (pt) derivado de amida, referida composição farmacêutica e agente terapêutico.
ATE486840T1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
ES2182357T3 (es) Nueva utilizacion de budesonide y formoterol.
TR199902396T2 (xx) Analjezik birle�ik.
CY1110462T1 (el) Θεραπεια της ηπατικης ινωσης με αντισωματα εναντιον της ενσωματινης (ιντεγκρινης) αλφα v βητα 6
PL357944A1 (en) Intradermal-penetration agents for topical local anesthetic administration
GT199800126A (es) Terapia de combinacion.
NO20053106D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
EE200100256A (et) Ravimi manustamise vahend, eriti progestiinide jaöstrogeenide manustamiseks
BR0002607A (pt) Composições lìquidas rapidamente absorvidas
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
DE69932510D1 (de) Vaskularisierungsinhibitoren
MXPA02012851A (es) Pirrolidinas 1,3-disustituidas y 1,3,3-trisustituidas como ligandos del receptor de histamina-3 y sus aplicaciones terapeuticas.
DK0784613T3 (da) Colchicinderivater og den terapeutiske anvendelse deraf
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
ATE457318T1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
IT1286496B1 (it) Composizione farmaceutica orale ad attivita' antipiretica,analgesica ed antiinfiammatoria
FR2707369B1 (fr) Réservoir, en particulier, du type bouteille à gaz.
ES2152315T3 (es) Xamoneline tartrato.
DE69841260D1 (de) Bakterielle pheromone und deren verwendungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0923941

Country of ref document: EP